Press Releases

Year

Jul 27, 2021

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif. , July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today

Jul 12, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. , July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming

Jun 30, 2021

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021 ALLO-605 is the Third Prong of the Company’s Clinical Strategy to Target BCMA for the Treatment of Multiple Myeloma TurboCAR TM Technology Provides Selective, Programmable Cytokine Signaling Designed to Improve Function and

Jun 21, 2021

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer

Veteran pharmaceutical executive with proven cell and gene therapy development experience in Asia , formerly of WuXi AppTec Shanghai and the joint venture JW Therapeutics SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI --(BUSINESS WIRE)--Jun. 21, 2021-- Allogene Overland Biopharm (Allogene

Jun 04, 2021

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrated Six Month Complete

May 20, 2021

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. , May 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming

May 19, 2021

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

ALLO-501 ALPHA Trial Produced Durable Complete Responses (CR) with Longest Ongoing CR at 15 Months in Both Large B Cell Lymphoma (LBCL) and Follicular Lymphoma (FL) Overall Response Rate (ORR) of 75% and CR Rate of 50% Across Histologies in CAR T Naïve Patients, on Par with Data from Pivotal Trials

May 12, 2021

Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021

Webinar Scheduled for 2:30 PM PT / 5:30 PM ET SOUTH SAN FRANCISCO, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on

May 05, 2021

Allogene Therapeutics Reports First Quarter 2021 Financial Results

CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Longer Term Follow-Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be Included Allogene to Host

Apr 28, 2021

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20